Focusing on individual patient needs, Cancer Chemotherapy, Immunotherapy and Biotherapy: Principles and Practice, Seventh Edition, provides thorough, comprehensive information from Drs. Bruce A. Chabner, Dan L. Longo, and an authoritative team of clinicians and scientists working at renowned cancer centers across the globe. It covers fundamental information about mechanism of action, pharmacokinetics, clinical toxicity, and drug interactions, all essential to the safe and effective use of the drug.
1. Cover - p. i 2. Half Title Page - p. i 3. Title Page - p. iii 4. Copyright Page - p. iv 5. Contributors - p. v 6. Preface - p. x 7. Acknowledgments - p. xi 8. Contents - p. xiii 9. Section I: Basic Principles of Cancer Treatment - p. 1 10. 1 Clinical Strategies for Cancer Treatment: The Role of Drugs - p. 2 11. 2 Target Identification and Drug Discovery - p. 17 12. 3 Clinical Drug Development and Approval - p. 35 13. 4 Pharmacogenomics and Cancer Therapeutics - p. 45 14. 5 Delivering Anticancer Drugs to Brain Tumors - p. 64 15. 6 Antifolates - p. 89 16. 7 5-Fluoropyrimidines - p. 120 17. 8 Cytidine Analogues - p. 142 18. 9 Purine Analogues - p. 158 19. 10 Antimitotic Drugs - p. 173 20. 11 Alkylating and Methylating Agents - p. 195 21. 12 Platinum Analogues - p. 222 22. 13 Topoisomerase Inhibitors - p. 236 23. 14 Bleomycin, Mitomycin C, Yondelis, and Other Antibiotics - p. 257 24. 15 Epigenetic Agents in Hematology and Oncology - p. 272 25. 16 Differentiating Agents in Acute Promyelocytic Leukemia - p. 290 26. 17 Asparaginase - p. 296 27. 18 Proteasome Inhibitors - p. 303 28. 19 Cereblon-Mediated Degraders - p. 323 29. Section II: Targeted Agents - p. 337 30. 20 Tyrosine Kinase Inhibitors - p. 338 31. 21 Mitogen-Activated Protein Kinase Pathway - p. 361 32. 22 The PI3K/AKT/mTOR Signaling System - p. 375 33. 23 Cyclin-Dependent Kinase Inhibitors - p. 391 34. 24 Drugs Targeting the ABL and Janus Kinases - p. 427 35. 25 Bruton Tyrosine Kinase Inhibitors - p. 451 36. 26 Angiogenesis Inhibitors - p. 463 37. Section III: Hormone Antagonists for Breast Cancer - p. 479 38. 27 Endocrine Therapy of Breast Cancer - p. 480 39. 28 Hormonal Therapy for Prostate Cancer - p. 499 40. Section IV: Immune-Based Therapies - p. 513 41. 29 Monoclonal Antibodies - p. 514 42. 30 Cytokine Therapy for Cancer - p. 544 43. 31 Adoptive Cellular Therapy - p. 566 44. 32 Cancer Vaccines - p. 590 45. 33 Viral Xenogenization - p. 595 46. 34 Immunotherapeutic Control of Cancer - p. 607 47. Section V: Supportive Care - p. 641 48. 35 Antiemetics - p. 642 49. 36 Hematopoietic Growth Factors - p. 656 50. 37 Cancer and Coagulopathy - p. 670 51. Index - p. 691
No hay muestra disponible
No hay ficha técnica disponible
Focusing on individual patient needs, Cancer Chemotherapy, Immunotherapy and Biotherapy: Principles and Practice, Seventh Edition, provides thorough, comprehensive information from Drs. Bruce A. Chabner, Dan L. Longo, and an authoritative team of clinicians and scientists working at renowned cancer centers across the globe. It covers fundamental information about mechanism of action, pharmacokinetics, clinical toxicity, and drug interactions, all essential to the safe and effective use of the drug.
1. Cover - p. i 2. Half Title Page - p. i 3. Title Page - p. iii 4. Copyright Page - p. iv 5. Contributors - p. v 6. Preface - p. x 7. Acknowledgments - p. xi 8. Contents - p. xiii 9. Section I: Basic Principles of Cancer Treatment - p. 1 10. 1 Clinical Strategies for Cancer Treatment: The Role of Drugs - p. 2 11. 2 Target Identification and Drug Discovery - p. 17 12. 3 Clinical Drug Development and Approval - p. 35 13. 4 Pharmacogenomics and Cancer Therapeutics - p. 45 14. 5 Delivering Anticancer Drugs to Brain Tumors - p. 64 15. 6 Antifolates - p. 89 16. 7 5-Fluoropyrimidines - p. 120 17. 8 Cytidine Analogues - p. 142 18. 9 Purine Analogues - p. 158 19. 10 Antimitotic Drugs - p. 173 20. 11 Alkylating and Methylating Agents - p. 195 21. 12 Platinum Analogues - p. 222 22. 13 Topoisomerase Inhibitors - p. 236 23. 14 Bleomycin, Mitomycin C, Yondelis, and Other Antibiotics - p. 257 24. 15 Epigenetic Agents in Hematology and Oncology - p. 272 25. 16 Differentiating Agents in Acute Promyelocytic Leukemia - p. 290 26. 17 Asparaginase - p. 296 27. 18 Proteasome Inhibitors - p. 303 28. 19 Cereblon-Mediated Degraders - p. 323 29. Section II: Targeted Agents - p. 337 30. 20 Tyrosine Kinase Inhibitors - p. 338 31. 21 Mitogen-Activated Protein Kinase Pathway - p. 361 32. 22 The PI3K/AKT/mTOR Signaling System - p. 375 33. 23 Cyclin-Dependent Kinase Inhibitors - p. 391 34. 24 Drugs Targeting the ABL and Janus Kinases - p. 427 35. 25 Bruton Tyrosine Kinase Inhibitors - p. 451 36. 26 Angiogenesis Inhibitors - p. 463 37. Section III: Hormone Antagonists for Breast Cancer - p. 479 38. 27 Endocrine Therapy of Breast Cancer - p. 480 39. 28 Hormonal Therapy for Prostate Cancer - p. 499 40. Section IV: Immune-Based Therapies - p. 513 41. 29 Monoclonal Antibodies - p. 514 42. 30 Cytokine Therapy for Cancer - p. 544 43. 31 Adoptive Cellular Therapy - p. 566 44. 32 Cancer Vaccines - p. 590 45. 33 Viral Xenogenization - p. 595 46. 34 Immunotherapeutic Control of Cancer - p. 607 47. Section V: Supportive Care - p. 641 48. 35 Antiemetics - p. 642 49. 36 Hematopoietic Growth Factors - p. 656 50. 37 Cancer and Coagulopathy - p. 670 51. Index - p. 691
No hay muestra disponible
No hay ficha técnica disponible
